Skip to content

Diffuse Bio vs Generate:Biomedicines

Diffuse Bio logo

Diffuse Bio

We build generative AI for protein therapeutics

9 employees · est. 2022

VS
Generate:Biomedicines logo

Generate:Biomedicines

Pioneering generative biology to create breakthrough therapeutics

335 employees · est. 2018 · Somerville, United States

Generate:Biomedicines is the older company (2022 vs 2018); Generate:Biomedicines is the larger of the two.

Side-by-Side Comparison

Diffuse Bio Generate:Biomedicines
Founded
2022 2018 older
Headquarters
Not tracked yet Somerville, United States
Employees
9 335 larger
Industry
Biotechnology, Pharmaceutical Biotechnology, Pharmaceutical
Funding Stage
Not tracked yet IPO
Total Funding
$130.00K $1.09B
Funding Rounds
4 6
Services
AI-powered protein design, Protein binder optimization, Therapeutics advancement, Data-driven biological research Generative biology for novel medicines, The Generate Platform™ for drug discovery, Clinical development of therapeutic drugs
Target Customers
Biotechnology companies, Pharmaceutical industries, Research institutions, Academic labs Healthcare providers, Biotech companies, Pharmaceutical industry, Medical researchers
Taxonomy
Generative AIProtein TherapeuticsDrug DiscoveryBiopharmaceuticalsComputational BiologyTherapeutic Development +6 Generative BiologyDrug DevelopmentTherapeuticsProtein-based ModalitiesBreakthrough MedicinesMedicine Programming +3
Website
diffuse.bio generatebiomedicines.com
Diffuse Bio logo

About Diffuse Bio

Diffuse Bio, founded in 2022, is a budding innovator in the fields of Biotechnology and Pharmaceutical. Their core focus is encapsulated in their slogan: "We build generative AI for protein therapeutics." This signifies their commitment to leveraging cutting-edge technology to enhance protein therap...

Generate:Biomedicines logo

About Generate:Biomedicines

Generate:Biomedicines, founded in 2018, is innovatively bridging cutting-edge technology and life sciences. Operating within the Biotechnology and Pharmaceutical industries, this United States-based company is at the forefront of using generative biology to create groundbreaking therapeutics, as enc...

Also comparing in this category

Comparing more than these two?

Get Diffuse Bio, Generate:Biomedicines and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Diffuse Bio compare?

A PDF of Diffuse Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Diffuse Bio was founded in 2022, with 9 employees. Diffuse Bio, founded in 2022, is a budding innovator in the fields of Biotechnology and Pharmaceutical. Their core focus is encapsulated in their slogan: "We build generative AI for protein therapeuti. Generate:Biomedicines was founded in 2018, based in Somerville, United States, with 335 employees. Generate:Biomedicines, founded in 2018, is innovatively bridging cutting-edge technology and life sciences. Operating within the Biotechnology and Pharmaceutical industries, this United States-based c.
Diffuse Bio has raised $130.00K and Generate:Biomedicines $1.09B. Latest stage: Generate:Biomedicines IPO.
Both work in Biotechnology and Pharmaceutical.

Compare Diffuse Bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Diffuse Bio on 8 Nov 2026, and Generate:Biomedicines on 21 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout